Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 21c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.98, $0.21 better than the analyst estimate of $2.77. Revenue for the quarter came in at $444.61 million versus the consensus estimate of $434.87 million.

"The first quarter was highlighted by strong revenue growth, cash flow generation and execution across the organization that led to significant progress toward our 2018 goals," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The recent submission of our supplemental NDA for Xyrem for pediatric narcolepsy patients and FDA acceptance of our NDA for solriamfetol for excessive sleepiness in patients with narcolepsy or OSA result from our focused investment in advancing our promising R&D pipeline. Over the next 18 months, we look forward to fueling our portfolio with innovative product candidates and delivering on multiple regulatory milestones and product launches."

GUIDANCE:

Jazz Pharmaceuticals sees FY2018 EPS of $12.75-$13.25, versus the consensus of $12.78. Jazz Pharmaceuticals sees FY2018 revenue of $1.88-1.93 billion, versus the consensus of $1.89 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Stifel Canada Starts BlackBerry (BB) at Buy
• Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy